Who was studied?
An 85-year-old woman with postoperative oligometastatic gallbladder adenosquamous carcinoma who declined chemotherapy.
What does the publication report?
Following SBRT, pembrolizumab and GM-CSF, PET/CT showed complete metabolic response at 6 months. Reported PFS was 25 months and OS 29 months; subsequent progression was fatal.
Safety findings
Grade 1 anemia and nausea and a grade 2 angioma-like rash were reported; no grade ≥3 toxicity was observed.
How should we interpret it?
A related triplet case, not a PRaG-series clinical trial. Metabolic remission is distinct from cure.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
PD-1 Inhibitor and GM-CSF in Oligometastatic Gallbladder Adenosquamous Carcinoma: A Case Report · DOI: 10.54457/DR.202602001
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.